Microcap Ledger Decoy Therapeutics Inc. $DCOY
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Houston, TX
- Fiscal year end
- December 31
- Shares outstanding
- 655,185 [10-Q 2026-08-12]
What the company doesAI summary of filing
Decoy Therapeutics Inc. is a pre-clinical stage biotechnology company developing peptide conjugate therapeutics using its proprietary IMP³ACT platform, which combines artificial intelligence and machine learning with rapid synthesis techniques. The company has not generated revenue from product sales and is focused on developing designable multi-antivirals (D-MAVs) targeting infectious diseases, particularly respiratory viruses, as well as exploratory peptide-based proteolysis targeting chimeras (P-PROTACs) for oncology applications. The company generates no revenue and is supported by grant funding from organizations including The Gates Foundation and BARDA, along with capital raised through public offerings. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $227.6K | −$4.60M | −$5.54M | $8.29M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | — | $12.52M | −$4.83M | $10.71M | [DEF 14A 2026-06-04] |
| FY ended Dec 2024 | — | $5.58M | −$4.53M | $2.43M | [DEF 14A 2026-06-04] |
- Quarterly cash burn
- −$2.77M
- Cash runway Estimate
- ~9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 1,441,157 | [10-Q 2024-11-14] |
| 2025-03-17 | 1,745,730 | [10-K 2025-03-21] |
| 2025-05-09 | 2,127,286 | [10-Q 2025-05-14] |
| 2025-08-11 | 7,645,594 | [10-Q 2025-08-12] |
| 2025-11-12 | 5,862,178 | [10-Q 2025-11-14] |
| 2026-03-17 | 531,968 | [10-K 2026-03-31] |
| 2026-05-07 | 531,968 | [10-Q 2026-05-08] |
| 2026-08-12 | 655,185 | [10-Q 2026-08-12] |
- Shelf registration
- S-1 filed 2026-10-07; no effectiveness notice found in EDGAR [S-1 2026-10-07]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-01-02. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-01-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-01-02] |
| 2025-04-25 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-25] |
| 2025-03-28 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-03-28] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-31 | Lieber Jonathan I | grant | 2,000 | — | [4 2026-09-02] |
| 2026-08-31 | Pierce Frederick Ii | grant | 33,455 | — | [4 2026-09-02] |
| 2026-08-31 | Marschel Peter Klaus | grant | 3,900 | — | [4 2026-09-02] |
| 2026-08-31 | Rosenblum Mark J | grant | 9,682 | — | [4 2026-09-02] |
| 2026-08-31 | Hibner Barbara Louise | grant | 4,216 | — | [4 2026-09-02] |
| 2026-08-31 | Hanish Arnold C | grant | 3,000 | — | [4 2026-09-02] |
| 2026-08-31 | Lammers Paul | grant | 2,000 | — | [4 2026-09-02] |
| 2026-08-31 | Burleson Tess | grant | 2,000 | — | [4 2026-09-02] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | S-1 | Registration statement |
| 2026-09-23 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-09-15 | 8-K | Shareholder vote results |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-04 | DEF 14A | Proxy statement |
| 2026-07-24 | PRE 14A | Proxy statement |
| 2026-07-17 | 424B3 | Prospectus or prospectus supplement |
| 2026-07-15 | 8-K | Shareholder vote results |
| 2026-07-10 | S-1 | Registration statement |
| 2026-06-29 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-06-15 | S-1 | Registration statement |
Alerts for $DCOY
Email me when Decoy Therapeutics Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.